Avertix Guardian System Evaluated for Cost-Effectiveness in ACS Patients

February 18, 2025—Avertix Medical, Inc. recently announced new data confirming the cost-effectiveness of the company’s Guardian system in high-risk acute coronary syndrome (ACS) patients. The Guardian system is a real-time, continuous heart attack detection and patient alerting system.

The analysis leveraged data from the pivotal ALERTS clinical trial and was complemented by findings from relevant literature, noted Avertix.

According to the company, the data underscore the economic value of real-time intracardiac monitoring and alerting to heart attacks. The study was conducted by investigators from Duke Clinical Research Institute in Durham, North Carolina. Gillian D. Sanders Schmidler, PhD, et al published the findings in Future Cardiology (2025;21:83-93).

“Reducing delay between onset of occlusion and guideline-directed medical management is a well-accepted treatment goal for high-risk ACS patients,” commented Dr. Schmidler in the company’s press release. “Our analysis supports that the use of the Guardian system with these patients not only improves health outcomes but is economically attractive when compared to standard of care.”

As summarized in the press release, the analysis demonstrated that the Guardian system has an incremental cost-effectiveness ratio of $58,668 per quality-adjusted life year (QALY) compared to current practice. This incremental cost per QALY falls within conventional cost-effectiveness thresholds and is similar to that found for other implantable cardiac technologies, thereby reinforcing Guardian’s economic viability in cardiac care.

The company noted that the FDA-approved Guardian implantable heart attack warning system is designed to detect early warning signs of cardiac events and alert patients in real time, even in cases of silent ischemia. The study supports the case for expanding Guardian’s adoption among health care providers, payers, and policymakers, highlighting its role in reducing emergency care costs and improving long-term patient outcomes, noted Avertix.